FfDL : A Flexible Multi-tenant Deep Learning Platform

Deep learning (DL) is becoming increasingly popular in several application domains and has made several new application features involving computer vision, speech recognition and synthesis, self-driving automobiles, drug design, etc. feasible and accurate. As a result, large scale on-premise and cloud-hosted deep learning platforms have become essential infrastructure in many organizations. These systems accept, schedule, manage and execute DL training jobs at scale. This paper describes the design, implementation and our experiences with FfDL, a DL platform used at IBM. We describe how our design balances dependability with scalability, elasticity, flexibility and efficiency. We examine FfDL qualitatively through a retrospective look at the lessons learned from building, operating, and supporting FfDL; and quantitatively through a detailed empirical evaluation of FfDL, including the overheads introduced by the platform for various deep learning models, the load and performance observed in a real case study using FfDL within our organization, the frequency of various faults observed including unanticipated faults, and experiments demonstrating the benefits of various scheduling policies. FfDL has been open-sourced.Comment: MIDDLEWARE 201

A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment

Multidrug resistance (MDR) in tumor cells is a significant obstacle to the success of chemotherapy in many cancers. The purpose of this research is to test the possibility of docetaxel-loaded poly (ε-caprolactone)/Pluronic F68 (PCL/Pluronic F68) nanoparticles to overcome MDR in docetaxel-resistance human breast cancer cell line. Docetaxel-loaded nanoparticles were prepared by modified solvent displacement method using commercial PCL and self-synthesized PCL/Pluronic F68, respectively. PCL/Pluronic F68 nanoparticles were found to be of spherical shape with a rough and porous surface. The nanoparticles had an average size of around 200 nm with a narrow size distribution. The in vitro drug release profile of both nanoparticle formulations showed a biphasic release pattern. There was an increased level of uptake of PCL/Pluronic F68 nanoparticles in docetaxel-resistance human breast cancer cell line, MCF-7 TAX30, when compared with PCL nanoparticles. The cytotoxicity of PCL nanoparticles was higher than commercial Taxotere®in the MCF-7 TAX30 cell culture, but the differences were not significant (p > 0.05). However, the PCL/Pluronic F68 nanoparticles achieved significantly higher level of cytotoxicity than both of PCL nanoparticles and Taxotere®(p < 0.05), indicating docetaxel-loaded PCL/Pluronic F68 nanoparticles could overcome multidrug resistance in human breast cancer cells and therefore have considerable potential for treatment of breast cancer